Bristol Myers Squibb CO BMY
We take great care to ensure that the data presented and summarized in this overview for BRISTOL MYERS SQUIBB CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BMY
View all-
Vanguard Group Inc Valley Forge, PA189MShares$10.9 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY159MShares$9.14 Billion0.15% of portfolio
-
State Street Corp Boston, MA92.9MShares$5.35 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY77.9MShares$4.49 Billion0.33% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA61MShares$3.51 Billion0.61% of portfolio
-
Geode Capital Management, LLC Boston, MA43.2MShares$2.49 Billion0.18% of portfolio
-
Capital International Investors Los Angeles, CA42.6MShares$2.46 Billion0.44% of portfolio
-
Morgan Stanley New York, NY28MShares$1.61 Billion0.11% of portfolio
-
Primecap Management CO Pasadena, CA23.4MShares$1.35 Billion0.9% of portfolio
-
Northern Trust Corp Chicago, IL21.2MShares$1.22 Billion0.18% of portfolio
Latest Institutional Activity in BMY
Top Purchases
Top Sells
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Insider Transactions at BMY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 04
2024
|
Phil M Holzer SVP and Controller |
SELL
Open market or private sale
|
Direct |
700
-5.62%
|
$38,500
$55.62 P/Share
|
Nov 01
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Open market or private purchase
|
Direct |
1,830
+2.86%
|
$98,820
$54.67 P/Share
|
Nov 01
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,488
-1.43%
|
$80,352
$54.32 P/Share
|
Nov 01
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
55
-0.05%
|
-
|
Nov 01
2024
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,964
+2.77%
|
-
|
Oct 02
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-24.72%
|
$87,344
$53.76 P/Share
|
Oct 02
2024
|
Cari Gallman EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
4,558
+40.61%
|
-
|
Aug 01
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
384
-15.4%
|
$18,432
$48.17 P/Share
|
Aug 01
2024
|
Cari Gallman EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,061
+29.85%
|
-
|
Apr 01
2024
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
SELL
Payment of exercise price or tax liability
|
Direct |
1,196
-18.31%
|
$62,192
$52.99 P/Share
|
Apr 01
2024
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
BUY
Exercise of conversion of derivative security
|
Direct |
3,306
+33.6%
|
-
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-26.04%
|
$229,119
$53.79 P/Share
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
4,569
-16.83%
|
-
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,016
+41.58%
|
-
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
16,660
-1.58%
|
$882,980
$53.79 P/Share
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
SELL
Other acquisition or disposition
|
Direct |
14,153
-1.29%
|
-
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
46,784
+4.01%
|
-
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,965
-5.92%
|
$104,145
$53.79 P/Share
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Other acquisition or disposition
|
Direct |
2,789
-6.77%
|
-
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,143
+18.16%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 451K shares |
---|---|
Open market or private purchase | 1.83K shares |
Payment of exercise price or tax liability | 153K shares |
---|---|
Other acquisition or disposition | 132K shares |
Open market or private sale | 700 shares |